A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma.

被引：0
|
作者：
Wang, Feng
Xia, Jin
Meng, Xiangrui
Ji, Yinghua
Yang, Xiuli
Hong, Yong-Gui
Wang, Junsheng
Cui, Donghai
Luo, Zhiquan
机构：
[1] Zhengzhou Univ, Affiliated Canc Hosp 1, Henan Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[2] Anyang Tumor Hosp, Anyang, Henan, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 1, Dept Med Oncol, Zhengzhou, Peoples R China
[4] Xinxiang Med Univ, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China
[5] Nanyang Med Coll, Affiliated Hosp 1, Nanyang, Peoples R China
[6] Anyang Tumor Hosp, Dept Oncol, Anyang, Henan, Peoples R China
[7] Xinyang Tumor Hosp, Xinyang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16007
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A single-arm, open phase II clinical trial of anti programmed death-1 antibody SHR-1210 combined with nimotuzumab as second-line treatment of advanced esophageal squamous cell carcinoma.
    Wang, Feng
    Meng, Xiangrui
    Fan, Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
    Wang Feng
    Wang Junsheng
    Wu Tao
    Hong Yonggui
    Meng Xiangrui
    Ren Zhonghai
    Guo Yanzhen
    Yang Xiuli
    Shi Pei
    Yang Jiamei
    Fan Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [3] Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
    Meng, Xiangrui
    Wu, Tao
    Hong, Yonggui
    Fan, Qingxia
    Ren, Zhonghai
    Guo, Yanzhen
    Yang, Xiuli
    Shi, Pei
    Yang, Jiamei
    Yin, Xianzhe
    Luo, Zhiquan
    Xia, Jin
    Zhou, Yue
    Xu, Mengli
    Liu, Enjie
    Jiang, Guozhong
    Li, Shenglei
    Zhao, Feng
    Ma, Chi
    Ma, Chuanxiang
    Hou, Zhiguo
    Li, Jing
    Wang, Junsheng
    Wang, Feng
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : 245 - 253
  • [4] Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
    Wang Feng
    Qi Yu
    Meng Xiangrui
    Fan Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [5] Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.
    Wang, Feng
    Qi, Yu
    Meng, Xiangrui
    Fan, Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC
    Gao, G.
    Wang, Y.
    Ren, S.
    Zhao, J.
    Chen, G.
    Chen, J.
    Gu, K.
    Guo, R.
    Pan, Y.
    Wang, Q.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S819 - S819
  • [7] Clinical study on the second-line treatment of advanced esophageal squamous cell carcinoma with camrelizumab combined with apatinib and irinotecan: A single-arm, multicenter, phase II study
    He, Yifu
    Li, Chenghui
    Zhang, Fenglin
    Hu, Bing
    Sun, Yubei
    Xia, Xiaoyang
    Zhang, Yanshun
    Wang, Gang
    Xu, Tengyun
    Duan, Aixiong
    Wu, Shusheng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC)
    Peer, Avivit
    Neumann, Avivit
    Keizrnan, Daniel
    Frank, Stephen Jay
    Berger, Raanan
    Leitzin, Larisa
    Pinto, Ester
    Neiman, Victoria
    Rosenbaum, Eli
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [9] A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC).
    Peer, Avivit
    Neumann, Avivit
    Keizman, Daniel
    Frank, Stephen Jay
    Berger, Raanan
    Leitzin, Larisa
    Pinto, Ester
    Neiman, Victoria
    Rosenbaum, Eli
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial
    Gong, Lei
    Yang, Yueyang
    Zhang, Hongdian
    Qiao, Yufeng
    Wang, Haitong
    Ren, Peng
    Tang, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345